Title : Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.

Pub. Date : 2004 Jul 15

PMID : 15246889






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Rosiglitazone treatment significantly reduced C-reactive protein (median 0.56 mg/L [interquartile range 0.33 to 1.02] to 0.33 mg/L [interquartile range 0.26 to 0.40], p <0.01), von Willebrand factor (139 +/- 47 to 132 +/- 44 IU/dl, p = 0.02), insulin resistance index (p = 0.05), and mean low-density lipoprotein (LDL) density (p <0.001) compared with placebo. Rosiglitazone C-reactive protein Homo sapiens